(CME) CME - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US12572Q1058
Stock:
Total Rating 54
Risk 62
Buy Signal 0.39
| Risk 5d forecast | |
|---|---|
| Volatility | 17.5% |
| Relative Tail Risk | 3.18% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.05 |
| Alpha | 21.80 |
| Character TTM | |
|---|---|
| Beta | 0.039 |
| Beta Downside | 0.238 |
| Drawdowns 3y | |
|---|---|
| Max DD | 11.65% |
| CAGR/Max DD | 2.00 |
EPS (Earnings per Share)
Revenue
Description: CME CME
CME Group Inc., together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services. The company provides clearing house services, including clearing, settling, and guaranteeing futures and options contracts, and cleared swaps products traded through its exchanges; and trade processing and risk mitigation services. In addition, the company offers a range of market data services, including real-time and historical data services. It serves professional traders, financial institutions, institutional and individual investors, corporations, manufacturers, producers, governments, and central banks. The company was formerly known as Chicago Mercantile Exchange Holdings Inc. and changed its name to CME Group Inc. in July 2007. The company was founded in 1898 and is headquartered in Chicago, Illinois.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 4.04b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.58 > 1.0 |
| NWC/Revenue: -115.0% < 20% (prev 11.74%; Δ -126.7% < -1%) |
| CFO/TA 0.02 > 3% & CFO 4.16b > Net Income 4.04b |
| Net Debt (-1.00b) to EBITDA (5.72b): -0.18 < 3 |
| Current Ratio: 0.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (360.2m) vs 12m ago 0.05% < -2% |
| Gross Margin: 86.09% > 18% (prev 0.86%; Δ 8523 % > 0.5%) |
| Asset Turnover: 3.88% > 50% (prev 4.46%; Δ -0.58% > 0%) |
| Interest Coverage Ratio: 41.98 > 6 (EBITDA TTM 5.72b / Interest Expense TTM 129.7m) |
Altman Z'' 0.24
| A: -0.04 (Total Current Assets 152.80b - Total Current Liabilities 160.30b) / Total Assets 198.42b |
| B: 0.03 (Retained Earnings 5.71b / Total Assets 198.42b) |
| C: 0.03 (EBIT TTM 5.45b / Avg Total Assets 167.94b) |
| D: 0.17 (Book Value of Equity 28.73b / Total Liabilities 169.70b) |
| Altman-Z'' Score: 0.24 = B |
Beneish M -2.99
| DSRI: 1.05 (Receivables 639.2m/573.1m, Revenue 6.52b/6.13b) |
| GMI: 1.00 (GM 86.09% / 86.13%) |
| AQI: 0.92 (AQ_t 0.23 / AQ_t-1 0.25) |
| SGI: 1.06 (Revenue 6.52b / 6.13b) |
| TATA: -0.00 (NI 4.04b - CFO 4.16b) / TA 198.42b) |
| Beneish M-Score: -2.99 (Cap -4..+1) = A |
What is the price of CME shares?
As of February 26, 2026, the stock is trading at USD 307.36 with a total of 3,828,924 shares traded.
Over the past week, the price has changed by +1.59%, over one month by +8.21%, over three months by +11.48% and over the past year by +24.88%.
Over the past week, the price has changed by +1.59%, over one month by +8.21%, over three months by +11.48% and over the past year by +24.88%.
Is CME a buy, sell or hold?
CME has received a consensus analysts rating of 3.39.
Therefor, it is recommend to hold CME.
- StrongBuy: 4
- Buy: 3
- Hold: 7
- Sell: 4
- StrongSell: 0
What are the forecasts/targets for the CME price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 299.3 | -2.6% |
| Analysts Target Price | 299.3 | -2.6% |
CME Fundamental Data Overview February 24, 2026
P/E Trailing = 27.6314
P/E Forward = 22.779
P/S = 16.9865
P/B = 3.4484
P/EG = 5.589
Revenue TTM = 6.52b USD
EBIT TTM = 5.45b USD
EBITDA TTM = 5.72b USD
Long Term Debt = 3.42b USD (from longTermDebt, two quarters ago)
Short Term Debt = 55.2m USD (from shortTermDebt, two quarters ago)
Debt = 3.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.00b USD (from netDebt column, last quarter)
Enterprise Value = 109.64b USD (110.76b + Debt 3.42b - CCE 4.55b)
Interest Coverage Ratio = 41.98 (Ebit TTM 5.45b / Interest Expense TTM 129.7m)
EV/FCF = 26.85x (Enterprise Value 109.64b / FCF TTM 4.08b)
FCF Yield = 3.72% (FCF TTM 4.08b / Enterprise Value 109.64b)
FCF Margin = 62.63% (FCF TTM 4.08b / Revenue TTM 6.52b)
Net Margin = 62.02% (Net Income TTM 4.04b / Revenue TTM 6.52b)
Gross Margin = 86.09% ((Revenue TTM 6.52b - Cost of Revenue TTM 907.0m) / Revenue TTM)
Gross Margin QoQ = 85.38% (prev 84.55%)
Tobins Q-Ratio = 0.55 (Enterprise Value 109.64b / Total Assets 198.42b)
Interest Expense / Debt = 1.29% (Interest Expense 44.0m / Debt 3.42b)
Taxrate = 26.00% (410.4m / 1.58b)
NOPAT = 4.03b (EBIT 5.45b * (1 - 26.00%))
Current Ratio = 0.95 (Total Current Assets 152.80b / Total Current Liabilities 160.30b)
Debt / Equity = 0.12 (Debt 3.42b / totalStockholderEquity, last quarter 28.73b)
Debt / EBITDA = -0.18 (Net Debt -1.00b / EBITDA 5.72b)
Debt / FCF = -0.25 (Net Debt -1.00b / FCF TTM 4.08b)
Total Stockholder Equity = 27.92b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.41% (Net Income 4.04b / Total Assets 198.42b)
RoE = 14.48% (Net Income TTM 4.04b / Total Stockholder Equity 27.92b)
RoCE = 17.37% (EBIT 5.45b / Capital Employed (Equity 27.92b + L.T.Debt 3.42b))
RoIC = 12.97% (NOPAT 4.03b / Invested Capital 31.07b)
WACC = 5.91% (E(110.76b)/V(114.18b) * Re(6.06%) + D(3.42b)/V(114.18b) * Rd(1.29%) * (1-Tc(0.26)))
Discount Rate = 6.06% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.08%
[DCF] Terminal Value 87.36% ; FCFF base≈3.90b ; Y1≈4.37b ; Y5≈5.79b
[DCF] Fair Price = 476.4 (EV 170.27b - Net Debt -1.00b = Equity 171.27b / Shares 359.5m; r=5.91% [WACC]; 5y FCF grow 13.81% → 2.90% )
EPS Correlation: 89.72 | EPS CAGR: 7.53% | SUE: 1.83 | # QB: 2
Revenue Correlation: 88.90 | Revenue CAGR: 5.55% | SUE: -0.31 | # QB: 0
EPS next Quarter (2026-03-31): EPS=3.04 | Chg7d=+0.001 | Chg30d=+0.100 | Revisions Net=+10 | Analysts=12
EPS current Year (2026-12-31): EPS=11.92 | Chg7d=+0.034 | Chg30d=+0.216 | Revisions Net=+9 | Growth EPS=+6.5% | Growth Revenue=+6.0%
EPS next Year (2027-12-31): EPS=12.65 | Chg7d=+0.027 | Chg30d=+0.236 | Revisions Net=+5 | Growth EPS=+6.1% | Growth Revenue=+4.7%
[Analyst] Revisions Ratio: +0.83 (11 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.3% (Discount Rate 7.9% - Earnings Yield 3.6%)
[Growth] Growth Spread = +1.3% (Analyst 5.6% - Implied 4.3%)
P/E Forward = 22.779
P/S = 16.9865
P/B = 3.4484
P/EG = 5.589
Revenue TTM = 6.52b USD
EBIT TTM = 5.45b USD
EBITDA TTM = 5.72b USD
Long Term Debt = 3.42b USD (from longTermDebt, two quarters ago)
Short Term Debt = 55.2m USD (from shortTermDebt, two quarters ago)
Debt = 3.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.00b USD (from netDebt column, last quarter)
Enterprise Value = 109.64b USD (110.76b + Debt 3.42b - CCE 4.55b)
Interest Coverage Ratio = 41.98 (Ebit TTM 5.45b / Interest Expense TTM 129.7m)
EV/FCF = 26.85x (Enterprise Value 109.64b / FCF TTM 4.08b)
FCF Yield = 3.72% (FCF TTM 4.08b / Enterprise Value 109.64b)
FCF Margin = 62.63% (FCF TTM 4.08b / Revenue TTM 6.52b)
Net Margin = 62.02% (Net Income TTM 4.04b / Revenue TTM 6.52b)
Gross Margin = 86.09% ((Revenue TTM 6.52b - Cost of Revenue TTM 907.0m) / Revenue TTM)
Gross Margin QoQ = 85.38% (prev 84.55%)
Tobins Q-Ratio = 0.55 (Enterprise Value 109.64b / Total Assets 198.42b)
Interest Expense / Debt = 1.29% (Interest Expense 44.0m / Debt 3.42b)
Taxrate = 26.00% (410.4m / 1.58b)
NOPAT = 4.03b (EBIT 5.45b * (1 - 26.00%))
Current Ratio = 0.95 (Total Current Assets 152.80b / Total Current Liabilities 160.30b)
Debt / Equity = 0.12 (Debt 3.42b / totalStockholderEquity, last quarter 28.73b)
Debt / EBITDA = -0.18 (Net Debt -1.00b / EBITDA 5.72b)
Debt / FCF = -0.25 (Net Debt -1.00b / FCF TTM 4.08b)
Total Stockholder Equity = 27.92b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.41% (Net Income 4.04b / Total Assets 198.42b)
RoE = 14.48% (Net Income TTM 4.04b / Total Stockholder Equity 27.92b)
RoCE = 17.37% (EBIT 5.45b / Capital Employed (Equity 27.92b + L.T.Debt 3.42b))
RoIC = 12.97% (NOPAT 4.03b / Invested Capital 31.07b)
WACC = 5.91% (E(110.76b)/V(114.18b) * Re(6.06%) + D(3.42b)/V(114.18b) * Rd(1.29%) * (1-Tc(0.26)))
Discount Rate = 6.06% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.08%
[DCF] Terminal Value 87.36% ; FCFF base≈3.90b ; Y1≈4.37b ; Y5≈5.79b
[DCF] Fair Price = 476.4 (EV 170.27b - Net Debt -1.00b = Equity 171.27b / Shares 359.5m; r=5.91% [WACC]; 5y FCF grow 13.81% → 2.90% )
EPS Correlation: 89.72 | EPS CAGR: 7.53% | SUE: 1.83 | # QB: 2
Revenue Correlation: 88.90 | Revenue CAGR: 5.55% | SUE: -0.31 | # QB: 0
EPS next Quarter (2026-03-31): EPS=3.04 | Chg7d=+0.001 | Chg30d=+0.100 | Revisions Net=+10 | Analysts=12
EPS current Year (2026-12-31): EPS=11.92 | Chg7d=+0.034 | Chg30d=+0.216 | Revisions Net=+9 | Growth EPS=+6.5% | Growth Revenue=+6.0%
EPS next Year (2027-12-31): EPS=12.65 | Chg7d=+0.027 | Chg30d=+0.236 | Revisions Net=+5 | Growth EPS=+6.1% | Growth Revenue=+4.7%
[Analyst] Revisions Ratio: +0.83 (11 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.3% (Discount Rate 7.9% - Earnings Yield 3.6%)
[Growth] Growth Spread = +1.3% (Analyst 5.6% - Implied 4.3%)